World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
77405
World Ranking
4431
National Ranking
2414

Joaquim Bellmunt publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joaquim Bellmunt sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 899 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joaquim Bellmunt D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joaquim Bellmunt sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 115 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joaquim Bellmunt is affiliated with the Beth Israel Deaconess Medical Center in the United States. Their research primarily focuses on medicine, with extensive work in surgery, oncology, pulmonary and respiratory medicine, molecular biology, and cancer research.

The scientist's main topics of research include bladder and urothelial cancer treatments, urinary and genital oncology studies, cancer immunotherapy and biomarkers, esophageal cancer research and treatment, renal cell carcinoma treatment, prostate cancer treatment and research, and multiple and secondary primary cancers.

Joaquim Bellmunt has published research in several frequent venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Journal of Urology
  • European Urology
  • Urologic Oncology Seminars and Original Investigations

Recent papers featuring Bellmunt's authorship cover a range of advanced topics in urothelial carcinoma and immunotherapy. These include:

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, 2020, New England Journal of Medicine
  • ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, 2021, Nature
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Frequent coauthors collaborating with Bellmunt include:

  • Petros Grivas
  • Thomas Powles
  • Srikala S. Sridhar
  • Shilpa Gupta
  • Yohann Loriot

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

    Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    A. Gordon Robertson;Jaegil Kim;Hikmat Al-Ahmadie;Joaquim Bellmunt

  • EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

    Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

    Philip Cornford;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

  • 前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療

    A Heidenreich;J Bellmunt;M Bolla;S Joniau

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Bernard Escudier;Joaquim Bellmunt;Sylvie Négrier;Emilio Bajetta

  • A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

    Aurélie Kamoun;Aurélien de Reyniès;Yves Allory;Yves Allory;Gottfrid Sjödahl

  • Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

    Joaquim Bellmunt;Christine Théodore;Tomasz Demkov;Boris Komyakov

  • Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

    P Dombernowsky;I Smith;G Falkson;R Leonard

  • Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

    Maria De Santis;Joaquim Bellmunt;Graham Mead;J. Martijn Kerst

  • Guidelines on Prostate Cancer

    A. Heidenreich;J. Bellmunt;M. Bolla;S. Joniau

  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;J. Bellmunt;M. Bolla;S. Joniau

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Cora N. Sternberg
Cora N. Sternberg Cornell University
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Eliezer M. Van Allen
Eliezer M. Van Allen Harvard University
Gregory R. Pond
Gregory R. Pond McMaster University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine but seeking alternative or complementary career options, there are a variety of affordable online degrees to consider. Those aiming to become pharmacists can explore 3 year online pharmd programs, offering a flexible route to advanced pharmacy credentials.

If you are interested in the intersection of healthcare and technology, health information technology programs online provide training in data management, security, and analysis, which are essential skills in today’s medical landscape.

Another growing field is medical billing and coding, where you can earn certifications without breaking the bank. Learn more about medical coding certification cost and find cost-effective pathways to enter this essential healthcare role.

For those pursuing advanced practice in nursing, there are options for high-quality education at lower costs. Discover the cheapest online nurse practitioner programs and earn credentials that open up diverse patient care opportunities.

These online programs offer flexible solutions for building a successful career in healthcare—whether your passion is clinical work, technology, administration, or beyond.

Best Scientists Citing Joaquim Bellmunt

Trending Scientists

Recently Published Articles